STOCK TITAN

Atossa Therapeutics Inc - ATOS STOCK NEWS

Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.

Atossa Therapeutics Inc (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company pioneering novel therapies for breast cancer and breast health conditions. This page provides investors and healthcare stakeholders with comprehensive access to official press releases, clinical trial developments, and regulatory updates directly from the company.

Track progress on key initiatives including (Z)-endoxifen clinical trials, innovative drug delivery systems like intraductal microcatheter technology, and strategic partnerships. Our curated news collection ensures timely updates on FDA communications, research milestones, and intellectual property developments relevant to oncology therapeutics.

Discover updates across three primary categories: clinical research advancements in estrogen receptor-targeted treatments, regulatory filings for breast cancer therapies, and scientific collaborations enhancing drug delivery platforms. Each update is sourced from verified company communications to maintain accuracy and compliance.

Bookmark this page for streamlined access to Atossa's latest developments in selective estrogen receptor modulation and precision medicine. Regularly updated to serve as your primary resource for understanding the company's progress in addressing unmet needs in oncology care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences
-
Rhea-AI Summary
Atossa Therapeutics has fully enrolled the pharmacokinetic run-in cohort of its Phase 2 EVANGELINE study. The study is testing Atossa's patented SERM, (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with ER+/HER2- breast cancer. The goal of the PK run-in cohort is to determine if the 40mg dose delivers optimal plasma concentrations. Data is expected in Q3 of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
conferences
-
Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) reported its financial results for the year ended December 31, 2022, highlighting significant clinical advancements. The company initiated its Phase 2 EVANGELINE study for neoadjuvant treatment in premenopausal women with ER+ breast cancer and continues enrollment in the Karisma-Endoxifen study. Notably, Atossa added a new arm to the ongoing I-SPY 2 trial, evaluating (Z)-endoxifen. Financially, the company reported an operating loss of $27.7 million, a 35% increase from 2021, driven mostly by rising R&D costs. Cash reserves stood at approximately $111 million, supporting ongoing clinical endeavors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) announces its proprietary Selective Estrogen Receptor Modulator, (Z)-endoxifen, will be assessed in a new arm of the I-SPY 2 clinical trial targeting locally advanced breast cancer. This trial, involving approximately 20 patients, aims to evaluate treatment effectiveness prior to surgery. The study focuses on estrogen receptor-positive invasive breast cancer patients, who have high recurrence risks and require more effective treatments. Dr. Steven Quay highlighted the urgency of new alternatives for these patients. Atossa is also conducting two Phase 2 studies for (Z)-endoxifen with promising implications for breast cancer management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
Rhea-AI Summary

Atossa Therapeutics, Inc. (Nasdaq: ATOS) has announced its participation in the Sidoti Small-Cap Virtual Conference, scheduled for March 22-23, 2023. Dr. Steven Quay, the Company’s President and CEO, along with Kyle Guse, General Counsel and CFO, will present on March 23 at 1:00 PM Eastern Time. Investors can register for the live webcast through the event's website. A recording will also be made available post-conference on Atossa's investor relations page. Atossa focuses on developing innovative medicines for unmet medical needs in oncology, particularly breast cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
conferences
Atossa Therapeutics Inc

Nasdaq:ATOS

ATOS Rankings

ATOS Stock Data

80.49M
129.09M
0.06%
28.55%
7.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE